bioRASI, a full-service contract research organisation based in Aventura, US and with an international presence in Russia, Serbia, India, Brazil, Peru and Mexico, has acquired Ukrainian counterpart Sponsors Clinical Research Group (SCRG) for an undisclosed sum.
Formed in 2004, SCRG is a regulatory and clinical CRO that works in a broad range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.
bioRASI said the acquisition addressed ever-growing demand to optimise global clinical trials under pressure to accelerate drug-development timelines while minimising costs.
It also built on bioRASI’s “already commanding presence” throughout Eastern Europe.
Superior expertise
“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” commented bioRASI chairman Dr Boris Reznik.
Dr Veklych, executive director of SCRG, said the integrated set of tools embodied in the bioRASI Process Infrastructure “greatly enhances optimised project delivery capabilities”.
While SCRG has worked for a number of global trial sponsors and CROs, “we have never experienced the powers of project management comparable to that of bioRASI”, he added.
